Scientists test 'Tumor-Seeking' radioactive drug in hopeless cancer cases
NCT ID NCT06148636
Summary
This is an early safety study to find a safe dose of a new radioactive drug called [212Pb] VMT-alpha-NET for people with neuroendocrine tumors that have returned or stopped responding to other treatments. The main goal is to see how much radiation the kidneys can safely handle during treatment, not to cure the cancer. Participants receive two drug infusions about two months apart and are followed for life to monitor safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.